“a favorable trend”

Similarly to us, these reviews revealed a favorable trend for LI-BFR in muscle mass gain, however, this effect did not reach statistical significance.

Thus, the Perioperative chemotherapy versus surveillance in upper Tract urothelial cancer (POUT) trial revealed a significant improvement in DFS, MFS, and DSS with a favorable trend in OS for adjuvant chemotherapy in locally advanced UTUC.

42 Sulbactam-based regimens demonstrated a higher microbiological cure in most RCTs and a favorable trend in observational studies.

A favorable trend in OS was indicated and consistent results were observed across all key subgroups (Figs. 4 , 5 ).

An immunophenotypic classification that defined the top tertile of iTIL scores as the immune‐inflamed subtype produced a favorable trend in PFS for the immune‐inflamed group, whereas OS did not differ significantly (HR, 0.70; 95% CI, 0.46–1.06; p = 0.09 for PFS; HR, 1.00; 95% CI, 0.61–1.63; p = 0.99 for OS) (Figure 4B ).

[ 6 ] also demonstrates a favorable trend and exhibits much lower error compared to the other two models, yet it still holds an error of 201.83cp.

When remnant cholesterol was modeled as a categorical variable, we also observed a U-shaped association, whereas we did not observe a significantly greater or lower risk in the other three quartiles than in the lowest quartile, despite a favorable trend toward a lower risk in the third quartile [Q3: HR (95%CI): 0.67 (0.42-1.07)].

Despite the clinical advantage obtained by the earlier air leak cessation, a statistically significant reduction in the duration of the hospital stay was not found in patients receiving sealant application; although they showed a favorable trend towards shorter hospitalization, (air leakage is not the only major reason for postoperative hospitalization).

conventional DAPT strategies following PCI revealed a favorable trend for shorter DAPT durations.

The results revealed that compared to docetaxel, enzalutamide sequential therapy (HR: 0.22, 95% CI: 0.03–1.67) and enzalutamide combined therapy (HR: 0.46, 95% CI: 0.06–3.07) exhibited a favorable trend in enhancing the time to PSA progression in mHSPC patients ( Supplementary Material 6R ).

It should be noted that our results showed a favorable trend from 5 μM, a dose similar to that used in the abovementioned studies [ 11 , 12 ]; however, 10 μM was used for subsequent experiments to achieve clear statistical significance.

After a weighted average follow-up of 23 months, novel oral anticoagulants were associated with significant reductions in the risk of stroke or systemic embolism (OR=0.81 [0.71-0.92], I 2 =23%) all cause death (OR=0.88 [0.82-0.95], I 2 =0%), in comparison to warfarin, with a favorable trend for major bleeding (OR=0.83 [0.68-1.02], I 2 =73%).

The analysis was conducted with RWD from 17 observational studies and showed a favorable trend in outcomes and cost effectiveness for the sequence abiraterone acetate-enzalutamide compared to enzalutamide-abiraterone acetate.

Surgery showed a favorable trend of ORR for BMs from NSCLC but did not reach a statistical difference (RR: 1.04, 95% CrI: 0.89–1.21, common effect model). 3.5 Heterogeneity, consistency, and sensitivity analysis There was low global heterogeneity for the comparison of radiotherapy-associated regiments (I2 = 0% for OS, I2 = 0% for CNS-PFS, and I2 = 8% for ORR) and low to moderate heterogeneity for the comparison of ICIs (I2 = 22% for OS, I2 = 33% for CNS-PFS, and I2 = 25% for ORR).

Among other high-risk categories, including older patients (≥ 50 years; HR 0.25, 95% CI 0.02–3.74; p = 0.289), those with prior ATG exposure (HR 0.46, 95% CI 0.06–3.36; p = 0.489), and ABO-incompatible recipients (HR, 0.64, 95% CI 0.13–3.03; p = 0.510), a favorable trend was observed, though without statistical significance.

Although the percentages were lower, a favorable trend for full-time and part-time employment was observed for women [ 40 ].

Among them, only three concluded that PTR did not confer an OS benefit [ 41 , 53 , 55 ], whereas 11 reported a significant OS advantage associated with PTR [ 40 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ], and the remaining two suggested a favorable trend [ 42 , 54 ].

For other outcomes, such as kidney function, anthropometric measures, hematological markers, and TNF‐α, no statistically significant changes were observed, although a favorable trend was noted.

Conclusions: The addition of CDK4/6i to ET improves iDFS and shows a favorable trend in DRFS in early-stage HR+/HER2− breast cancer, highlighting the need for longer follow-up to clarify their long-term benefit. early-stage HR+/HER2− breast cancer CDK4/6 inhibitors endocrine therapy adjuvant therapy meta-analysis invasive disease-free survival abemaciclib ribociclib palbociclib Thi

In contrast, a favorable trend was shown in non-HDL-C, TC, and median TG levels [ 23 , 24 ].

Regarding overall outcomes, the complication rate showed a favorable trend.

The presence of a family caregiver in our study was accompanied by a favorable trend in terms of readmission and mortality in the short- and medium-term and attenuated at one year of follow-up.

Consequently, this variation was designated as “the therapeutic effect of PBS..” The results demonstrated that, irrespective of the specific condition (e.g., scratching the nose, runny nose, or sneezing), the therapeutic effect of PBS exhibited a favorable trend over time ( Fig. 4E ).

Although ECOG PS showed a favorable trend in patients with scores 0–1, this did not reach statistical significance in the adjustment.

Consistent with previous studies, 13 , 23 our data also confirm that ERAS does not impose additional burdens on liver reserve function - critical for hepatectomy patients, especially those with underlying liver diseases - supported by stable PALBI grade distributions and a favorable trend toward improved liver function.